Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Smith & Nephew's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Smith & Nephew's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Smith & Nephew's highest Yield on Cost was 3.67. The lowest was 1.49. And the median was 2.17.
MEX:SN1 N's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.44 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Smith & Nephew (MEX:SN1 N) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Smith & Nephew 5-Year Yield-on-Cost % Related Terms
MEX:SN1 N vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Smith & Nephew's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Smith & Nephew is calculated as
Smith & Nephew (MEX:SN1 N) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Smith & Nephew and its competitors. Over the past decade, Smith & Nephew's 5-Year Yield-on-Cost % has ranged from 1.49 to 3.67. According to the industry distribution chart, Smith & Nephew ranks #156 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 48.9%.
Is Smith & Nephew's 5-Year Yield-on-Cost % too high?
Smith & Nephew's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.49 to a high of 3.67. Based on the distribution chart, Smith & Nephew ranks #156 out of 319 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Smith & Nephew has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #156 out of 319 companies for 5-Year Yield-on-Cost %. This puts Smith & Nephew in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. Historically, Smith & Nephew's own 5-Year Yield-on-Cost % has ranged from 1.49 to 3.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.44, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Smith & Nephew (MEX:SN1 N) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is MXN265.52, compared to a current price of MXN256.55 — trading 3.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Smith & Nephew's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Smith & Nephew (MEX:SN1 N), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (MEX:SN1 N) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of MXN256.55 is trading 3.4% below its estimated GF Value™ of MXN265.52.
Key valuation signals for MEX:SN1 N:
5-Year Yield-on-Cost %: 0.00
GF Value™: MXN265.52 vs. price of MXN256.55 (3.4% below fair value)
No single metric tells the full story. See the MEX:SN1 N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
83GF Score
Get the complete analysis for MEX:SN1 N
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SN1 N has been successfully added to your 
